Pulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review

Mycoses. 2017 Oct;60(10):626-633. doi: 10.1111/myc.12642. Epub 2017 Jun 28.

Abstract

Pneumocystis jirovecii is the causative agent of Pneumocystis pneumonia (PcP), a common and often life-threatening opportunistic infection in HIV-infected patients. However, non-HIV, immunocompromised patients are at risk of PcP as well, whereas the mortality appears to be higher among these patients. Pneumocystis co-infections with other microorganisms are less frequent and only sparse reports of combined PcP and invasive pulmonary fungal infections exist in the literature, especially in the non-HIV patients. Two cases of pulmonary co-infections by P. jirovecii and Aspergillus fumigatus are presented. Both patients were non-HIV infected, the first one was suffering from crescentic IgA nephropathy under immunosuppressive treatment and the second from resistant non-Hodgkin lymphoma under chemotherapy. Both patients were treated with intravenous trimethoprim/sulphamethoxazole (TMP/SMX) combined with voriconazole. The first patient showed gradual clinical improvement while the outcome for the second patient was unfavourable. In addition, a literature review of the previous published cases of co-infection by P. jirovecii and other fungi in non-HIV patients was performed. Our target was to provide comprehensive information on this kind of infections, highlighting the importance of clinical suspicion.

Keywords: Aspergillus fumigatus; Pneumocystis jirovecii; Pneumocystis pneumonia; co-infection; non-HIV-patients.

Publication types

  • Case Reports
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / microbiology
  • Adult
  • Aged, 80 and over
  • Aspergillus fumigatus / physiology*
  • Coinfection* / drug therapy
  • Female
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / therapeutic use
  • Invasive Fungal Infections / drug therapy
  • Invasive Fungal Infections / microbiology
  • Lung / microbiology*
  • Male
  • Middle Aged
  • Pneumocystis carinii / physiology*
  • Pneumonia, Pneumocystis / drug therapy
  • Pneumonia, Pneumocystis / microbiology*
  • Pneumonia, Pneumocystis / mortality
  • Pulmonary Aspergillosis / complications*
  • Pulmonary Aspergillosis / drug therapy
  • Pulmonary Aspergillosis / microbiology
  • Pulmonary Aspergillosis / mortality
  • Retrospective Studies
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

Substances

  • Immunosuppressive Agents
  • Trimethoprim, Sulfamethoxazole Drug Combination